Skip to main content
Premium Trial:

Request an Annual Quote

Agilent, PathAI Forge Deal on Algorithm-Supported Assay Development

NEW YORK – Agilent Technologies and digital pathology firm PathAI are partnering to develop assays and distribute PathAI's software and algorithms to anatomic pathology laboratories, they announced on Wednesday.

Santa Clara, California-based Agilent and Boston-based PathAI said the multiyear deal covers the development of assays, including companion diagnostics and digital pathology tests.

"This partnership brings together our exceptional assay development capabilities, PathAI's expertise in digital algorithms, and Agilent's workflow expertise to offer research, translational medicine, and diagnostics solutions of the future," Agilent Companion Diagnostics Division VP Paul Beresford said in a statement.

Agilent will also distribute PathAI's AISight and AISight DX+ software and AIM PD-L1 NSCLC algorithm to anatomic pathology laboratories under a global distribution agreement, the firms said. The deal also lets Agilent commercialize algorithms later launched by PathAI.

Financial and other terms of the deals were not disclosed.

PathAI announced earlier this year the launch of its AISight digital pathology platform to support artificial intelligence-driven research and the firm's AIM-PD-L1 NSCLC RUO algorithm to analyze non-small cell lung cancer surgical specimens and provide quantification and visualizations of PD-L1 positivity.

"Incorporating AI into the start of the assay development process will maximize the assay's potential by surveying all possible data outputs, including novel scoring schemes and fully quantitative cut-points," PathAI CEO Andy Beck said in a statement. "We see this as a step change opportunity for organizations developing precision oncology therapies, further driving the industry's adoption of precision medicine."

PathAI also announced last year that it had forged a partnership with the Cleveland Clinic to use PathAI's pathology algorithms for translational research and clinical diagnostics. In 2021, Roche also signed an agreement with PathAI toward development of an embedded image analysis workflow for pathologists.